Therefore, agonistic anti-DCIR antibodies could provide therapeutic benefits for chronic diseases driven by neutrophil-mediated pathology, including chronic obstructive pulmonary disease (COPD), neutrophilic asthma, RA, and gouty arthritis. This evidence concerns the gene CLEC4A and chronic obstructive pulmonary disease.